小胶质细胞
去铁胺
髓鞘
白质
基因敲除
细胞生物学
化学
冲程(发动机)
神经保护
细胞质
药理学
DMT1型
医学
敌手
铁结合蛋白
髓鞘碱性蛋白
神经科学
神经胶质
线粒体
体外
溶酶体
白质营养不良
内科学
运输机
作者
Lingling Qiu,Yajie Zhang,Yushi Tang,Hongli Hu,Ying Zhang,Junwen Xue,Hao Wang,Yecheng Wang,Chunfeng Liu,Jia Jia,Jian Cheng,Yongjun Cao
标识
DOI:10.1002/advs.202511482
摘要
ABSTRACT White matter stroke (WMS) results in demyelinating changes and neurological deficits. However, the underlying molecular mechanisms of demyelination after stroke and the specific role of microglia in white matter rehabilitation remain incompletely elucidated. This study identifies a time‐dependent accumulation of iron in microglial lysosomes mediated by solute carrier family 11 member 1 (SLC11A1), which persists from 12 h to 14 days following WMS. This iron accumulation results in damaged lysosomal myelin debris uptake and degradation in microglia. Notably, iron chelation with deferoxamine (DFO), microglia‐specific knockdown of SLC11A1, and administration of LM22B‐10, a SLC11A1 antagonist identified in this study, effectively reduce lysosomal iron accumulation in microglia, enhance microglial uptake and clearance of myelin debris, and ultimately promote functional recovery after WMS. Furthermore, SLC11A1 functions as a H + /Fe 2+ antiporter that transports Fe 2+ from the cytoplasm into lysosomes both in vitro and in vivo. Collectively, these results highlight that targeting SLC11A1 represents a previously unrecognized therapeutic strategy for WMS repair with significant clinical implications.
科研通智能强力驱动
Strongly Powered by AbleSci AI